Abeona Therapeutics Inc vs Block Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Block Inc trades at $78.3 (market cap $47.50B). The key difference: Block Inc is far larger — about 112.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | XYZ | |
|---|---|---|
Market Cap | $421.19M | $47.50B |
Sector | Health | Technology |
52-Week High | $7.45 | $84.64 |
52-Week Low | $4.17 | $49.04 |
Enterprise Value | $276.10M | $42.41B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
XYZ trades at $77.97, down 1.28% on the day, with strong analyst support (75% buy ratings) and a $99.47 consensus price target. The stock shows bullish technical momentum with recent earnings beats in Q1 and Q2 2026, including Q2 EPS of $1.02 beating $0.871 estimates. Revenue reached $24.19B in 2025, though net margins remain thin at 1.43%. Recent news highlights Square's expanded credit card features and AI integration driving operational efficiency.
Outlook remains positive with raised 2026 guidance and 25% gross profit growth, though high P/E of 141.2 signals premium valuation. Key risks include competitive fintech pressure and execution on AI initiatives. Institutional buying and strong Cash App performance support upside potential toward price targets.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →